VXRT
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | 0.02 | $39M | -$3M |
| 2025 Q4 | 0.23 | $104M | $31M |
| 2025 Q3 | -0.04 | $72M | $2M |
| 2025 Q2 | -0.07 | $40M | -$16M |
| 2025 Q1 | -0.07 | $21M | -$10M |
| 2024 Q4 | -0.05 | $15M | -$7M |
| 2024 Q3 | -0.08 | $5M | -$4M |
| 2024 Q2 | -0.09 | $6M | -$12M |